🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
A Real-world Study to Evaluate the Effectiveness of Intravascular Lithotripsy in Moderate to Severe Calcification Lesion of Lower Extremity Femoropopliteal Artery
NCT06636968Peripheral Arterial Disease
Shanghai Zhongshan Hospital
Observational
200
Shanghai
2024-07-31
Active, closed
SAVE-PCI: NyokAssist™ Small-Bore VAD vs. IABP in Elective High-Risk PCI
NCT07010965High-Risk PCI
magAssist, Inc.
Not applicable
236
Beijing, Changsha, Guangzhou, Hangzhou, Harbin, Lanzhou, Shanghai, Taiyuan
2024-07-31
Not yet open
Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.
NCT06500247The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Qilu Hospital of Shandong University
Phase 2
43
Jinan
2024-07-31
Recruiting
The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06587425Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital
Phase 2
50
Shanghai
2024-07-31
Recruiting
Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation
NCT06308952Cerebrovascular Event, Stent Stenosis, Ischemic Stroke, Hemorrhagic Stroke
Duan Chuanzhi
Phase 4
354
Guangzhou
2024-07-30
Recruiting
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
NCT06470191Primary Membranous Nephropathy
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
216
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanning, Nantong, Qingdao
2024-07-30
Not yet open
Electroacupuncture Treatment of Behavioral and Psycological Symptoms in Patients With Alzheimer's Disease
NCT06523309BPSD (Behavioral and Psycological Symptoms of Dementia), Alzheimer's Dementia
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Observational
1,000
Beijing, Fuzhou, Harbin
2024-07-30
Active, closed
Early Combined Use of Dexamethasone Intravitreal Implant and Anti-VEGF in the Treatment of DME.
NCT06846073Diabetic Macular Edema (DME)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
70
Hangzhou
2024-07-30
Recruiting
68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma
NCT06519760Carbonic Anhydrase IX, PET-CT, Clear Cell Renal Cell Carcinoma
Peking University First Hospital
Not applicable
200
Beijing
2024-07-30
Recruiting
Risk Warning Model of Postoperative Delirium and Long-term Cognitive Dysfunction in Elderly Patients
NCT06423547Postoperative Delirium, Postoperative Neurocognitive Disorder, Surgery
Xuanwu Hospital, Beijing
Observational
10,000
Beijing
2024-07-30
Recruiting
IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)
NCT06513429Refractory Systemic Lupus Erythematosus
Peking University Third Hospital
Not applicable
6
Beijing
2024-07-30
By invitation
Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis
NCT06629623Idiopathic Pulmonary Fibrosis
Chu Hongling
Observational
310
Beijing
2024-07-30
Recruiting
Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules
NCT06423235Thyroid Nodule
Xintian Pharmaceutical
Phase 4
234
Chongqing, Xiamen, Guangzhou, Shenzhen, Shunde, Wuhan, Nanjing, Xuzhou
2024-07-30
Recruiting
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
NCT06675214Nasopharyngeal Carcinoma, De-escalation Therapy
Sun Yat-sen University
Phase 3
586
Zhuhai
2024-07-30
Recruiting
A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
NCT06505395Gastrointestinal Neuroendocrine Pancreatic Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2
90
Beijing
2024-07-30
By invitation
Clinical Trial to Evaluate the Effectiveness and Safety of a Remote Automated Ultrasound Diagnostic System for Automated Ultrasound Examinations: a Prospective, Multicenter Study
NCT06487312Ultrasound, Thyroid, Carotid Artery, Liver
Tongji Hospital
Observational
1,000
Wuhan
2024-07-30
Recruiting
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
NCT06512051Advanced or Metastatic Non-small Cell Lung Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
248
Beijing
2024-07-30
Recruiting
Efficacy of Two HMOs in Chinese Infants
NCT06361719Healthy Infants
Société des Produits Nestlé (SPN)
Not applicable
262
Shanghai
2024-07-29
Recruiting
Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia
NCT06532552Acute Myeloid Leukemia, Adult, Newly Diagnosed
The First Affiliated Hospital of Soochow University
Phase 2
172
Suzhou
2024-07-29
Recruiting
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
NCT06522555Diffuse Large B-Cell Lymphoma
Ruijin Hospital
Phase 3
100
Shanghai
2024-07-29
Active, closed
Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer
NCT06507371Rectal Cancer
Sir Run Run Shaw Hospital
Phase 3
170
Hanzhou
2024-07-29
Recruiting
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
NCT06573593Alopecia Areata, Janus Kinase Inhibitors
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
150
Hangzhou
2024-07-29
Recruiting
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
NCT07356531Liver Cancer
JIANGSU SHENMING Medical Technology CO., Ltd
Not applicable
216
Hefei, Beijing, Nanning, Guiyang, Shijiazhuang, Anyang, Luoyang, Zhengzhou
2024-07-29
Recruiting
Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases
NCT06619808Metabolic Dysfunction-associated Steatotic Liver Disease, Hepatic Steatosis, Non-alcoholic Fatty Liver Diseases
Jinling Hospital, China
Not applicable
150
Nanjing
2024-07-29
Recruiting
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06083207Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
116
Beijing, Nanning, Wuhan, Nanjing, Suzhou, Xuzhou, Nanchang, Shanghai
2024-07-29
Recruiting
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations
NCT06430437Non-Small Cell Lung Cancer With HER2- Mutations
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
300
Shanghai
2024-07-29
Active, closed
Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)
NCT06524947Acute Gastroenteropathy Due to Norovirus
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase 3
6,600
Nanning, Changsha, Chengdu
2024-07-27
Recruiting
A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT06492005Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 2
160
Shanghai
2024-07-26
Recruiting
Efficacy and Influencing Factors of Deep Transcranial Magnetic Stimulation in the Treatment of OCD
NCT06692114Obsessive-Compulsive Disorder
Zhen Wang
Not applicable
70
Shanghai
2024-07-26
Recruiting
Development and Prospective Validation of a Digital Pathology-based Artificial Intelligence Diagnostic Model for Pan-cancer Lymphatic Metastasis
NCT06517979Cancer, Lymphatic Metastasis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
10,000
Guangzhou
2024-07-26
Recruiting
Intravascular Ultrasound-Guided PCI in Patients With Chronic Kidney Disease
NCT06567938Coronary Artery Disease, Chronic Kidney Diseases
First Affiliated Hospital Xi'an Jiaotong University
Not applicable
1,528
Xi'an
2024-07-25
Recruiting
Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
NCT06498154Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
200
Tianjin
2024-07-25
Recruiting
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy
NCT06641895Duchenne Muscular Dystrophy (DMD)
Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1
6
Shanghai
2024-07-25
Recruiting
A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.
NCT07070674Acute Graft-versus-Host Disease
Accro Bioscience (Suzhou) Limited
Phase 1
24
Tianjin
2024-07-25
Recruiting
Preoperative Oral Midazolam to Postoperative Pain Relief in Sleep Disturbance or Anxiety Patients With Colorectal Cancer
NCT06407518Preoperative, Sleep Disturbance, Anxiety, Midazolam
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
280
Guangzhou
2024-07-24
Not yet open
A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus
NCT06373991Lupus Erythematosus, Systemic
EdiGene Inc.
Phase 1
12
Luoyang
2024-07-24
Recruiting
Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment
NCT06529549Metastatic Castration-resistant Prostate Cancer
Sun Yat-sen University
Observational
30
Guangzhou
2024-07-24
Recruiting
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Beijing, Guangzhou, Zhengzhou, Shenyang, Jinan, Shanghai
2024-07-24
Recruiting
Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer
NCT06562920Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
Zhejiang Cancer Hospital
Phase 2
20
Hangzhou
2024-07-24
Recruiting
A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia
NCT06972537Pneumonia
Shandong University
Not applicable
42
Jinan
2024-07-24
Active, closed
Accuracy, Stability and Safety of Orthodontic Mini-implant Template in the Infrazygomatic Crest Zone
NCT06786221Dental Implants, Dental Implantation
Universiti Sains Malaysia
Not applicable
24
Beijing
2024-07-24
Recruiting
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
NCT06821048Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
Weijia Fang, MD
Phase 1
18
Hangzhou
2024-07-24
Recruiting
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
NCT06454578Carcinoma, Hepatocellular
Qilu Hospital of Shandong University
Phase 2
30
Jinan
2024-07-24
Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
NCT06500052Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Guangzhou
2024-07-24
Recruiting
Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy
NCT07309185Stomach Neoplasms
Shandong Tumor Hospital
Phase 2
66
Jinan
2024-07-24
Active, closed
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180Cervical Cancer
Merck Sharp & Dohme LLC
Phase 3
686
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Nanning
2024-07-24
Recruiting
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
NCT07093970Advanced Solid Tumors
Lepu Biopharma Co., Ltd.
Phase 1/2
343
Beijing, Shanghai
2024-07-24
Recruiting
Donafenib Combined With Anti-PD-1 Antibody for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
NCT06787911Thyroid Cancer
Yu Wang
Phase 2
14
Shanghai
2024-07-24
Active, closed
Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma
NCT06524466Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage
Sun Yat-sen University
Phase 2
35
Guangzhou
2024-07-23
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Recruiting
PulseSelect™ PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Beijing, Fuzhou, Harbin, Kunming, Nanjing, Shanghai, Shenzhen, Ürümqi
2024-07-23
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
Application of Autologous Adipose Stromal Vascular Fraction in the Treatment of Premature Ovarian Insufficiency
NCT06481969Premature Ovarian Insufficiency
Rui Yang
Not applicable
260
Beijing
2024-07-23
Recruiting
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
NCT06764836Advanced Solid Tumors, HCC
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1
108
Shanghai
2024-07-23
Recruiting
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
NCT06351150Vasodilatory Shock
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
214
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Qingyuan
2024-07-23
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
BeOne Medicines
Phase 1/2
630
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-07-23
Recruiting
A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
NCT06512116Advanced Solid Tumor
Shanghai Institute Of Biological Products
Phase 1
196
Beijing
2024-07-23
Recruiting
PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
NCT06755775Diffuse Large B-Cell Lymphoma
Ruijin Hospital
Observational
150
Shanghai
2024-07-23
Active, closed
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
NCT06376084Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms
AstraZeneca
Observational
532
Shanghai
2024-07-23
Recruiting
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
102
Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Jiangmen
2024-07-22
Recruiting
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
NCT06484153To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma, To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer, Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
25
Wuhan
2024-07-22
Active, closed
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals
Phase 3
446
Bengbu, Beijing, Guangzhou, Guanzhou, Liuzhou, Xingtai, Luoyang, Wuhan
2024-07-22
Recruiting
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I
NCT06519552Mucopolysaccharidosis Type I
West China Hospital
Phase 1
6
Chengdu
2024-07-22
Recruiting
Born In Guangzhou Intervention Study
NCT05503849Pregnancy Outcomes, Child Development, Pregnancy Complications
Guangzhou Women and Children's Medical Center
Not applicable
1,160
Guangzhou
2024-07-22
Recruiting
Effect of Early Gait Training on Knee Cartilage Degeneration After Anterior Cruciate Ligament Reconstruction
NCT06368544Anterior Cruciate Ligament Injuries, Cartilage Degeneration
Peking University Third Hospital
Not applicable
60
Beijing
2024-07-22
Recruiting
Electroacupuncture for Dysmenorrhea Secondary to Adenomyosis
NCT06364592Dysmenorrhea, Adenomyosis, Electroacupuncture
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
30
Beijing
2024-07-21
Not yet open
Plasmodium Immunotherapy for Advanced Ovarian Cancer
NCT05924776Advanced Ovarian Cancer
CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.
Phase 2/3
30
Guangzhou
2024-07-20
Recruiting
The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life
NCT06535087Pediatric Asthma, Rhinitis, Allergic, Quality of Life
Wenjing Zhou
Observational
600
Shanghai
2024-07-20
Recruiting
An In-situ Detection for MicroRNA
NCT06529614Breast Cancer
Tongji Hospital
Observational
100
Wuhan
2024-07-20
Recruiting
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC
NCT06472713Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen
Phase 2
32
Zhuhai
2024-07-20
Recruiting
Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease
NCT06499233Pneumonia, Pneumocystis, Autoimmune Inflammatory Rheumatic Disease, Autoimmune Diseases, Connective Tissue Disease
Tongji Hospital
Phase 4
800
Wuhan
2024-07-20
Recruiting
Prediction of Significant Liver Fibrosis
NCT06509230Liver Fibrosis
Huang Haijun
Observational
700
Hangzhou
2024-07-20
Recruiting
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
NCT06400537Systemic Lupus Erythematosus
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
25
Wuhan, Taiyuan
2024-07-20
Not yet open
Electroacupuncture for the Treatment of Agitated Symptoms of Alzheimer's Disease
NCT06495957Agitation Associated With Alzheimer's Dementia, Alzheimer's Dementia
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
224
Beijing, Fuzhou, Harbin
2024-07-20
Recruiting
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
NCT06498622Hepatocellular Carcinoma
Anhui Provincial Hospital
Phase 2
45
Fuyang, Hefei
2024-07-20
Recruiting
A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients
NCT06441812Eosinophilic Asthma Patients
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
200
Chengdu
2024-07-19
Recruiting
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC
NCT06542588Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
29
Wuhan, Hubei
2024-07-19
Recruiting
Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA
NCT07291063Cholangiocarcinoma
Shanghai Zhongshan Hospital
Observational
50
Shanghai
2024-07-19
Recruiting
The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
NCT06623487Carcinoma, Non-Small-Cell Lung, PET / CT, Neoadjuvant Immunotherapy
Ruijin Hospital
Observational
30
Shanghai
2024-07-19
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3
286
Hefei, Beijing, Lanzhou, Harbin, Changsha, Changchun, Jinan, Chengdu
2024-07-19
Recruiting
IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients
NCT06765005Atopic Dermatitis
Shanghai Mabgeek Biotech.Co.Ltd
Phase 1/2
24
Hangzhou
2024-07-19
Active, closed
aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial
NCT06288659Aneurysmal Subarachnoid Hemorrhage, Intacranial Hypertension
Huashan Hospital
Not applicable
372
Shanghai
2024-07-19
Recruiting
A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors
NCT06553339Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1
60
Beijing
2024-07-19
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323Asthma
GlaxoSmithKline
Phase 3
150
Guangzhou, Shanghai, Tianjin
2024-07-19
By invitation
Cross Validation of Body Composition Measurement
NCT06453564Body Composition
John R. Speakman
Observational
30
Shenzhen
2024-07-19
Recruiting
Digital Therapy in Self-management of COPD Patients
NCT06776601Chronic Obstructive Pulmonary Disease
China-Japan Friendship Hospital
Not applicable
600
Beijing
2024-07-18
Recruiting
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT06517004Diffuse Large B Cell Lymphoma
Fudan University
Phase 1
9
Shanghai
2024-07-18
Recruiting
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
NCT06547203Colorectal Cancer Metastatic
Sun Yat-sen University
Phase 2
34
Guangzhou
2024-07-18
Recruiting
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06475131Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
21
Guangzhou
2024-07-18
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883Inflammatory Bowel Diseases, Crohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
2024-07-18
Active, closed
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
NCT06504199Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
39
Tianjin
2024-07-18
Recruiting
TP03HN106 in Patients With Critical Limb Ischemia
NCT06482892Critical Limb Ischemia
Talengen Institute of Life Sciences, Shenzhen, P.R. China.
Phase 2
15
Suzhou
2024-07-18
Recruiting
RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer
NCT06530316Thyroid Cancer
Fudan University
Observational
48
Shanghai
2024-07-18
Recruiting
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
NCT06536959Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Minimal Residual Disease
Beijing 302 Hospital
Phase 2
67
Beijing
2024-07-18
Recruiting
Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds
NCT06530537Cerebral Microbleeds, Stroke
Zhejiang Provincial People's Hospital
Phase 3
848
Hangzhou
2024-07-18
Active, closed
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
NCT06257966Type2 Diabetes Mellitus
Beijing Dongfang Biotech Co., Ltd.
Phase 3
600
Beijing
2024-07-17
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649Metastatic Colorectal Cancer
Amgen
Phase 3
450
2024-07-17
Recruiting
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
NCT06413654Neuromyelitis Optica Spectrum Disorders
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-07-17
Recruiting
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
NCT06517953Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q, EGFR S768I
Sun Yat-sen University
Phase 2
23
Guangzhou
2024-07-17
Active, closed
Open, Randomized Crossover Study on PK, PD, Biopotency, and Bioavailability of Insulin Capsules in Healthy Chinese Males
NCT06519604Diabete Mellitus
Shanghai Jiao Tong University School of Medicine
Phase 1
20
Shanghai
2024-07-17
Rows per page Showing 12101–12200 of 19052
Previous 120 121 122 123 124 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=122

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.